Share chart IMV Inc.
Extended chart
Simple chart
About IMV Inc.
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and MSI-H solid tumors, as well as in Phase I clinical trial for breast cancer. more details| Industry | Biotechnology |
|---|---|
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Сайт | https://www.imv-inc.com |
| Цена ао | 0.0001 |
| Change price per day: | 0% (0.0001) |
|---|---|
| Change price per week: | 0% (0.0001) |
| Change price per month: | 0% (0.0001) |
| Change price per 3 month: | 0% (0.0001) |
| Change price per half year: | 0% (0.0001) |
| Change price per year: | 0% (0.0001) |
| Change price per 3 year: | -100% (15) |
| Change price per 5 year: | -100% (21.8) |
| Change price per year to date: | 0% (0.0001) |
|
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
|||||||||||||||||||||||||||||||||||||
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Mr. Andrew Hall M.Sc. | CEO & Director | 680.6k | |
| Ms. Brittany Davison C.A., CPA | Chief Accounting Officer, Corporate Secretary & Director | 207.9k | 1990 (35 years) |
| Delphine Davan | Senior Director of Communications & Investor Relations | N/A | |
| Mr. Stephan Fiset M.B.A., M.Sc. | Vice President of Clinical Research | N/A | |
| Dr. Jeremy R. Graff Ph.D. | Chief Scientific Officer | 1971 (54 years) |
Address: Canada, Dartmouth. NS BB C, 130 Eileen Stubbs Avenue - open in Google maps, open in Yandex maps
Website: https://www.imv-inc.com
Website: https://www.imv-inc.com
